LYEL.US Lyell Immunopharma Inc

Healthcare Biotechnology USA Stocks
14.30 USD
Close of Nov 15, 2026
7.20 45.00
Market cap
USD 352M
P/E
-
P/B
1.82x
ROE
-79.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LYEL.US undervalued?

Graham number

The Graham number of Lyell Immunopharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lyell Immunopharma Inc fundamental analysis

No fundamental analysis for Lyell Immunopharma Inc yet.

Lyell Immunopharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial,…

Full company profile